METHODS: BALF and blood samples were obtained from 36 early-stage LUAD patients, with a control group of nineteen non-tumor individuals. The promoter methylation levels of SHOX2 and RASSF1A in all subjects were assessed using the human SHOX2 and RASSF1A gene methylation kit.
RESULTS: The methylation detection rate of SHOX2 and RASSF1A in plasma was 61.11%, slightly lower than that in BALF (66.7%). The Chi-square test revealed no significant difference in the methylation rate between BALF and plasma (P > 0.05). The area under the receiver operating characteristic (ROC) curve analysis for blood was 0.806 (95% CI, 0.677 to 0.900), while for BALF it was 0.781 (95% CI, 0.649 to 0.881). Additionally, we conducted an analysis on the correlation between SHOX2 and RASSF1A methylation levels in plasma with gender, age, tumor differentiation, pathologic classification, and other clinicopathological variables; however, no significant correlations were observed.
CONCLUSIONS: Measurement of SHOX2 and RASSF1A methylation for early diagnosis of LUAD can be achieved with high sensitivity and specificity by using plasma as a substitute for BALF samples.
方法:收集36例早期LUAD患者的BALF和血液样本,与19个非肿瘤个体的对照组。使用人SHOX2和RASSF1A基因甲基化试剂盒评估所有受试者中SHOX2和RASSF1A的启动子甲基化水平。
结果:血浆中SHOX2和RASSF1A的甲基化检出率为61.11%,略低于BALF(66.7%)。卡方检验显示BALF与血浆间甲基化率差异无统计学意义(P>0.05)。血液的受试者工作特征(ROC)曲线分析下面积为0.806(95%CI,0.677至0.900),而BALF为0.781(95%CI,0.649至0.881)。此外,我们对血浆中SHOX2和RASSF1A甲基化水平与性别的相关性进行了分析,年龄,肿瘤分化,病理分类,和其他临床病理变量;然而,没有观察到显著的相关性。
结论:使用血浆替代BALF样本,可以高灵敏度和特异性地测量SHOX2和RASSF1A甲基化以早期诊断LUAD。